RMB, Read the circuit court ruling in GSK v Teva. You will see some wording about the difference between a "skinny label" and a "partial label". This is important. GSK v Teva used a combination of label and advertising, in order to get the suit to the jury. Amarin v Hikma is using the same tactic. In GSK v Teva, the label itself was considered as infringing. The court declared it a partial label. Not a proper "skinny label". The label is part of the evidence asserted by Amarin in the suit. If Hikma is found guilty of induced infringement, the court will most likely declare the generic company has a partial label. That is the way the court avoided running a foul of Hatch Waxman. Every generic has the same label. Do you understand?
Sleven,
Market Data 
Markets 
AI
